Immunotherapeutic role of Ag85B as an adjunct to antituberculous chemotherapy

Journal of Immune Based Therapies and Vaccines

Volumn 9, Issue , 2011, Pages

  Sheikh, Javaid A ^a   Khuller, Gopal K ^a   Verma, Indu ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AG85B; DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 4; ISONIAZID; RECOMBINANT PROTEIN; RIFAMPICIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COUNT; BACTERIAL LOAD; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNIZATION; IMMUNOTHERAPY; LUNG; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; SPLEEN; TH1 CELL; TH2 CELL; TREATMENT RESPONSE; TUBERCULOSIS;

EID: 79959396817     PISSN: None     EISSN: 14768518     Source Type: Journal    
DOI: 10.1186/1476-8518-9-4     Document Type: Article

References (37)

1. Cox HS, Morrow M, Deutschmann PW. Long term efficacy of DOTS regimens for tuberculosis: systematic review. Bmj 2008, 336:484-487. 10.1136/bmj.39463.640787.BE, 2258398, 18250104.
2. Turner J, Rhoades ER, Keen M, Belisle JT, Frank AA, Orme IM. Effective pre exposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode. Infect Immun 2000, 68:1706-1709. 10.1128/IAI.68.3.1706-1709.2000, 97334, 10678993.
3. Repique CJ, Li A, Collins FM, Morris SL. DNA immunization in a mouse model of latent tuberculosis: effect of DNA vaccination on reactivation of disease and on reinfection with a secondary challenge. Infect Immun 2002, 70:3318-3323. 10.1128/IAI.70.7.3318-3323.2002, 128037, 12065468.
4. Lowrie DB, Tascon RE, Bonato VL, Lima VM, Faccioli LH, Stavropoulos E, Colston MJ, Hewinson RG, Moelling K, Silva CL. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999, 400:269-271. 10.1038/22326, 10421369.
5. Ha SJ, Jeon BY, Kim SC, Kim DJ, Song MK, Sung YC, Cho SN. Therapeutic effect of DNA vaccines combined with chemotherapy in a latent infection model after aerosol infection of mice with Mycobacterium tuberculosis. Gene Ther 2003, 10:1592-1599. 10.1038/sj.gt.3302057, 12907951.
6. Cardona PJ, Amat I, Gordillo S, Arcos V, Guirado E, Diaz J, Vilaplana C, Tapia G, Ausina V. Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine 2005, 23:1393-1398. 10.1016/j.vaccine.2004.09.008, 15661388.
7. Mwinga A, Nunn A, Ngwira B, Chintu C, Warndorff D, Fine P, Darbyshire J, Zumla A. Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial. Lancet 2002, 360:1050-1055. 10.1016/S0140-6736(02)11141-X, 12383985.
8. Johnson JL, Ssekasanvu E, Okwera A, Mayanja H, Hirsch CS, Nakibali JG, Jankus DD, Eisenach KD, Boom WH, Ellner JJ, Mugerwa RD. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am J Respir Crit Care Med 2003, 168:185-191. 10.1164/rccm.200211-1359OC, 12702550.
9. Guirado E, Amat I, Gil O, Diaz J, Arcos V, Caceres N, Ausina V, Cardona PJ. Passive serum therapy with polyclonal antibodies against Mycobacterium tuberculosis protects against post-chemotherapy relapse of tuberculosis infection in SCID mice. Microbes Infect 2006, 8:1252-1259. 10.1016/j.micinf.2005.12.004, 16702016.
10. Giri PK, Verma I, Khuller GK. Adjunct immunotherapy with Ag85 complex proteins based subunit vaccine in a murine model of Mycobacterium tuberculosis infection. Immunotherapy 2009, 1:31-37. 10.2217/1750743X.1.1.31, 20635971.
11. Boesen H, Jensen BN, Wilcke T, Andersen P. Human T-cell responses to secreted antigen fractions of Mycobacterium tuberculosis. Infect Immun 1995, 63:1491-1497. 173180, 7890415.
12. Mehra V, Gong JH, Iyer D, Lin Y, Boylen CT, Bloom BR, Barnes PF. Immune response to recombinant mycobacterial proteins in patients with tuberculosis infection and disease. J Infect Dis 1996, 174:431-434. 10.1093/infdis/174.2.431, 8699083.
13. Lozes E, Huygen K, Content J, Denis O, Montgomery DL, Yawman AM, Vandenbussche P, Van Vooren JP, Drowart A, Ulmer JB, Liu MA. Immunogenicity and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex. Vaccine 1997, 15:830-833. 10.1016/S0264-410X(96)00274-5, 9234526.
14. Ulmer JB, Liu MA, Montgomery DL, Yawman AM, Deck RR, DeWitt CM, Content J, Huygen K. Expression and immunogenicity of Mycobacterium tuberculosis antigen 85 by DNA vaccination. Vaccine 1997, 15:792-794. 10.1016/S0264-410X(96)00255-1, 9234515.
15. Kamath AT, Feng CG, Macdonald M, Briscoe H, Britton WJ. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect Immun 1999, 67:1702-1707. 96517, 10085007.
16. Doherty TM, Olsen AW, Weischenfeldt J, Huygen K, D'Souza S, Kondratieva TK, Yeremeev VV, Apt AS, Raupach B, Grode L, Kaufmann S, Andersen P. Comparative analysis of different vaccine constructs expressing defined antigens from Mycobacterium tuberculosis. J Infect Dis 2004, 190:2146-2153. 10.1086/425931, 15551213.
17. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 2000, 97:13853-13858. 10.1073/pnas.250480397, 17665, 11095745.
18. Olsen AW, Williams A, Okkels LM, Hatch G, Andersen P. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun 2004, 72:6148-6150. 10.1128/IAI.72.10.6148-6150.2004, 517547, 15385521.
19. Palendira U, Spratt JM, Britton WJ, Triccas JA. Expanding the antigenic repertoire of BCG improves protective efficacy against aerosol Mycobacterium tuberculosis infection. Vaccine 2005, 23:1680-1685. 10.1016/j.vaccine.2004.10.007, 15705472.
20. Bonato VL, Lima VM, Tascon RE, Lowrie DB, Silva CL. Identification and characterization of protective T cells in hsp65 DNA-vaccinated and Mycobacterium tuberculosis-infected mice. Infect Immun 1998, 66:169-175. 107873, 9423854.
21. Altare F, Durandy A, Lammas D, Emile JF, Lamhamedi S, Le Deist F, Drysdale P, Jouanguy E, Doffinger R, Bernaudin F, Jeppsson O, Gollob JA, Meinl E, Segal AW, Fischer A, Kumararatne D, Casanova JL. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 1998, 280:1432-1435. 10.1126/science.280.5368.1432, 9603732.
22. Stenger S, Hanson DA, Teitelbaum R, Dewan P, Niazi KR, Froelich CJ, Ganz T, Thoma-Uszynski S, Melian A, Bogdan C, Porcelli SA, Bloom BR, Krensky AM, Modlin RL. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 1998, 282:121-125.
23. Huygen K, Content J, Denis O, Montgomery DL, Yawman AM, Deck RR, DeWitt CM, Orme IM, Baldwin S, D'Souza C, Drowart A, Lozes E, Vandenbussche P, Van Vooren JP, Liu MA, Ulmer JB. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996, 2:893-898. 10.1038/nm0896-893, 8705859.
24. Tascon RE, Colston MJ, Ragno S, Stavropoulos E, Gregory D, Lowrie DB. Vaccination against tuberculosis by DNA injection. Nat Med 1996, 2:888-892. 10.1038/nm0896-888, 8705858.
25. Lowrie DB, Silva CL, Colston MJ, Ragno S, Tascon RE. Protection against tuberculosis by a plasmid DNA vaccine. Vaccine 1997, 15:834-838. 10.1016/S0264-410X(97)00073-X, 9234527.
26. Yu DH, Hu XD, Cai H. Efficient tuberculosis treatment in mice using chemotherapy and immunotherapy with the combined DNA vaccine encoding Ag85B, MPT-64 and MPT-83. Gene Ther 2008, 15:652-659. 10.1038/gt.2008.13, 18288210.
27. Silva CL, Bonato VL, Coelho-Castelo AA, De Souza AO, Santos SA, Lima KM, Faccioli LH, Rodrigues JM. Immunotherapy with plasmid DNA encoding mycobacterial hsp65 in association with chemotherapy is a more rapid and efficient form of treatment for tuberculosis in mice. Gene Ther 2005, 12:281-287. 10.1038/sj.gt.3302418, 15526006.
28. Roy E, Lowrie DB, Jolles SR. Current strategies in TB immunotherapy. Curr Mol Med 2007, 7:373-386. 10.2174/156652407780831557, 17584077.
29. Matteelli A, Migliori GB, Cirillo D, Centis R, Girard E, Raviglion M. Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control. Expert Rev Anti Infect Ther 2007, 5:857-871. 10.1586/14787210.5.5.857, 17914919.
30. Orme IM, Roberts AD, Griffin JP, Abrams JS. Cytokine secretion by CD4 T lymphocytes acquired in response to Mycobacterium tuberculosis infection. J Immunol 1993, 151:518-525.
31. Zhang M, Lin Y, Iyer DV, Gong J, Abrams JS, Barnes PF. T-cell cytokine responses in human infection with Mycobacterium tuberculosis. Infect Immun 1995, 63:3231-3234. 173444, 7622255.
32. Brindle RJ, Nunn PP, Githui W, Allen BW, Gathua S, Waiyaki P. Quantitative bacillary response to treatment in HIV-associated pulmonary tuberculosis. Am Rev Respir Dis 1993, 147:958-961.
33. Orme IM, McMurray DN, Belisle JT. Tuberculosis vaccine development: recent progress. Trends Microbiol 2001, 9:115-118. 10.1016/S0966-842X(00)01949-1, 11239788.
34. Ha SJ, Jeon BY, Youn JI, Kim SC, Cho SN, Sung YC. Protective effect of DNA vaccine during chemotherapy on reactivation and reinfection of Mycobacterium tuberculosis. Gene Ther 2005, 12:634-638. 10.1038/sj.gt.3302465, 15690060.
35. Li JM, Zhu DY. Therapeutic DNA vaccines against tuberculosis: a promising but arduous task. Chin Med J (Engl) 2006, 119:1103-1107.
36. Grover A, Ahmed MF, Singh B, Verma I, Sharma P, Khuller GK. A multivalent combination of experimental antituberculosis DNA vaccines based on Ag85B and regions of difference antigens. Microbes Infect 2006, 8:2390-2399. 10.1016/j.micinf.2006.04.025, 16962360.
37. Buccheri S, Reljic R, Caccamo N, Meraviglia S, Ivanyi J, Salerno A, Dieli F. Prevention of the post-chemotherapy relapse of tuberculous infection by combined immunotherapy. Tuberculosis (Edinb) 2009, 89:91-94.